Simian Adenoviruses As Vaccine Vectors | Zendy

Susan Morris | Zendy; Sarah Sebastian | Zendy; Alexandra J. Spencer | Zendy; Sarah C. Gilbert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simian Adenoviruses As Vaccine Vectors

Author(s) -

Susan Morris,

Sarah Sebastian,

Alexandra J. Spencer,

Sarah C. Gilbert

Publication year - 2016

Publication title -

future virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.462

H-Index - 34

eISSN - 1746-0808

pISSN - 1746-0794

DOI - 10.2217/fvl-2016-0070

Subject(s) - virology , immunogenicity , tropism , simian , vector (molecular biology) , biology , viral vector , tissue tropism , serotype , population , immune system , antigen , virus , immunology , medicine , gene , recombinant dna , genetics , environmental health

Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research